学术探索
学术期刊
新闻热点
数据分析
智能评审

Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

被引：84
作者：
Shepherd, FA [1 ]
Tsao, MS
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Univ Toronto, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 07期
关键词：
D O I：
10.1200/JCO.2005.04.4420
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1219 / 1220
页数：2
相关论文
共 8 条
  • [1] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    Eberhard, DA
    Johnson, BE
    Amler, LC
    Goddard, AD
    Heldens, SL
    Herbst, RS
    Ince, WL
    Jänne, PA
    Januario, T
    Johnson, DH
    Klein, P
    Miller, VA
    Ostland, MA
    Ramies, DA
    Sebisanovic, D
    Stinson, JA
    Zhang, YR
    Seshagiri, S
    Hillan, KJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 5900 - 5909
  • [2] Gumerlock PH, 2005, J CLIN ONCOL, V23, p623S
  • [3] Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study
    Hirsch, FR
    Varella-Garcia, M
    McCoy, J
    West, H
    Xavier, AC
    Gumerlock, P
    Bunn, PA
    Franklin, WA
    Crowley, J
    Gandara, DR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 6838 - 6845
  • [4] Selecting patients for epidermal growth factor receptor inhibitor treatment:: A FISH story or a tale of mutations?
    Johnson, BE
    Jänne, PAJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 6813 - 6816
  • [5] EGFR and ErbB2 mutation status in Japanese lung cancer patients
    Sasaki, H
    Shimizu, S
    Endo, K
    Takada, M
    Kawahara, M
    Tanaka, H
    Matsumura, A
    Iuchi, K
    Haneda, H
    Suzuki, E
    Kobayashi, Y
    Yano, M
    Fujii, Y
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (01) : 180 - 184
  • [6] Erlotinib in previously treated non-small-cell lung cancer
    Shepherd, FA
    Pereira, JR
    Ciuleanu, T
    Tan, EH
    Hirsh, V
    Thongprasert, S
    Campos, D
    Maoleekoonpiroj, S
    Smylie, M
    Martins, R
    van Kooten, M
    Dediu, M
    Findlay, B
    Tu, DS
    Johnston, D
    Bezjak, A
    Clark, G
    Santabárbara, P
    Seymour, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) : 123 - 132
  • [7] Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
    Takano, T
    Ohe, Y
    Sakamoto, H
    Tsuta, K
    Matsuno, Y
    Tateishi, U
    Yamamoto, S
    Nokihara, H
    Yamamoto, N
    Sekine, I
    Kunitoh, H
    Shibata, T
    Sakiyama, T
    Yoshida, T
    Tamura, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 6829 - 6837
  • [8] Erlotinib in lung cancer - Molecular and clinical predictors of outcome
    Tsao, MS
    Sakurada, A
    Cutz, JC
    Zhu, CQ
    Kamel-Reid, S
    Squire, J
    Lorimer, I
    Zhang, T
    Liu, N
    Daneshmand, M
    Marrano, P
    Santos, GD
    Lagarde, A
    Richardson, F
    Seymour, L
    Whitehead, M
    Ding, KY
    Pater, J
    Shepherd, FA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) : 133 - 144
1